Jean-JacquesBienaiméBiomarin Pharmaceutical Inc.董事长兼首席执行官亚博软件安全吗^
Jean-JacquesBienaiméjoined BioMarin’s Board in May 2005, the same time that he became the Company’s Chief Executive Officer, and was later named Chair of the Board in June 2015. From November 2002 to April 2005, Mr. Bienaimé served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. From 1992 to 1998, Mr. Bienaimé held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis), culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks. Mr. Bienaimé currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization (formerly known as The Biotechnology Industry Organization), an industry trade association. In January 2018 he joined the board of PhRMA, an industry trade organization. Mr. Bienaimé previously served on the boards of two public companies: Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014. He received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris.
Janssen Pharmaceuticals, Inc.前全球传染病和疫苗副总裁Elizabeth McKee Anderson于2019年7月加入董事会，在生物技术、制药和疫苗领域拥有超过30年的领导地位。从2003年到2014年退休，她在Johnson & Johnson担任高级领导职务。她最近担任全球副总裁,传染性疾病和疫苗詹森制药、强生公司,在那里她导演的商业开发抗病毒药物和疫苗的广泛投资组合负责全球战略营销,市场准入,和全球分析部门。在加入强生公司之前，她曾担任Wyeth Lederle Vaccines公司的副总裁兼总经理(从1997年到2002年)。她还曾在罗讷-普朗克罗勒和美国红十字会工作。她目前任职于私营公司Aro Biotherapeutics Inc.、Insmed Inc.、REVOLUTION Medicines Inc.和Context Therapeutics，以及上市公司Bavarian Nordic A/S和Huntsworth PLC的董事会。她持有Rutgers University的工程学士学位和Loyola University Maryland的工商管理硕士学位。
Willard H. Dere，M.D.内科教授，B. Lue and Hope S. Bettilyon总统赋予犹他州犹他大学临床和翻译科学中心的执行董事糖尿病研究主席，犹他大学健康科学中心^
Willard Dere, M.D., joined BioMarin’s Board in July 2016. Since November 2014, he has served as the Professor of Internal Medicine, B. Lue and Hope S. Bettilyon Presidential Endowed Chair in Internal Medicine for Diabetes Research, Executive Director of Personalized Health, and Co-Principal Investigator of the Center for Clinical & Translational Science at the University of Utah Health Sciences Center. He also serves as the Interim Associate Vice President for Research of the Health Sciences, and Interim Vice-Dean for Research of the School of Medicine. Prior to re-joining academia in November 2014, Dr. Dere was in the biopharmaceutical industry for 25 years. From 2003 until his retirement in 2014, Dr. Dere held multiple roles at Amgen, Inc., a biotechnology company, including serving as head of global development and either the international or corporate chief medical officer from December 2004 to October 2014. He began his career at Eli Lilly in 1989, and held a number of different global roles in clinical pharmacology, regulatory affairs, and both early-stage translational, and late-stage clinical research. He serves on the boards of three public biopharmaceutical companies: Mersana Therapeutics, Inc., Radius Health, Inc., and Seres Therapeutics, Inc. and concluded his service to Ocera Therapeutics, Inc. in December 2017. Since 2014, he has served on the scientific advisory board of the California Institute of Regenerative Medicine. Dr. Dere received a B.A. and an M.D. from the University of California, Davis. He trained in internal medicine at the University of Utah and endocrinology/metabolism at the University of California at San Francisco.
Elaine J. Heron，Ph.D.Amplyx Pharmaceuticals，Inc。主任^
Elaine J. Heron，Ph.D., joined BioMarin’s Board in July 2002. Dr. Heron served as Chair and Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private early stage drug development company, from February 2009 until October 2015, and she continues to serve as member of that company’s board. She is also a member of the boards of directors of Bavarian Nordic A/S, Insmed, Inc., Revolution Medicines Inc., Vala Sciences, Inc, as well as on the boards of directors of privately held companies: Aro Biotherapeutics, Inc., Context Therapeutics, DropWorks, Inc., and Palvella Therapeutics. From July 2001 to October 2008, Dr. Heron was Chair and Chief Executive Officer of Labcyte Inc., a private biotechnology company. Before joining Labcyte Inc., she spent six years in positions of increasing responsibility at the Applied Biosystems Group of Applera Corporation, a biotechnology company, including the position of General Manager and Vice President of Sales and Marketing. Dr. Heron earned a B.S. in chemistry with highest distinction, a Ph.D. in analytical biochemistry from Purdue University and an M.B.A. from Pepperdine University.
maykin ho，ph.d.齐明福合作伙伴的风险伙伴;Director Agios Pharmaceuticals Inc。;菲尼脲公司导演;Grail Inc。总监;Parexel.董事^
maykin ho，ph.d.2021年2月加入生物罗林董事会。何博士在医疗保健和金融行业拥有30多年的经验。她在Agios Pharmaceuticals Inc.，Fibrogen Inc.，Grail Inc.，Parexel，亚伦钻石艾滋病研究中心和蛋白质创新研究所担任。何博士也是炒风险伙伴的风险合作伙伴，香港联合交易所生物技术咨询小组成员。她是高盛集团的退休合伙人，曾担任全球医疗投资研究的高级生物技术分析师，以及医疗保健投资银行的咨询总监。在高盛在高盛之前，何博士在杜邦 - 梅克制药和杜邦德尼姆斯金属公司举行了各种管理职位，举行了各种管理职位，在杜邦 - 梅克医药和杜邦德尼姆苏尔斯＆公司的许可，战略规划，营销和研究中。她是哈佛医学院的博士后研究员，毕业于杜克大学富乐商学院的先进管理计划。何博士收到了博士学位。在微生物学和免疫学和B.S.中来自纽约州立大学，下斯特医疗中心。
罗伯特HombachBaxalta Inc.的前执行副总裁、首席财务官兼首席运营官;主任CarMax, Inc .);导演,Aptinyx Inc .)^
Robert J. Hombach joined BioMarin’s Board in September 2017. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc. (Baxter), a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. He served as Corporate Vice President and Chief Financial Officer of Baxter from July 2010 until the spin-off. From 2007 to 2011, he also served as Treasurer of Baxter and from 2004 to 2007, he was Vice President of Finance, Europe, Middle East and Africa. Prior to that, he served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the board of CarMax, Inc., a public company. He also serves on the board of Aptinyx, a clinical-stage biopharmaceutical company focused on neurological disorders. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management, and a B.S. in Finance暨裁决来自科罗拉多大学。
V. Bryan Lawlis，Ph.D.Aeglea Biotherapeutics，Inc。主任;Comherus Biosciences，Inc。总监;Geron Corporation主任^
Bryan Lawlis, Ph.D., joined BioMarin’s Board in June 2007. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc, a private biotechnology company. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation (Aradigm), a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, served as its President and Chief Executive Officer from 1996 to 1999, and served as Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis has served on the board of Geron Corporation, a public biopharmaceutical company, since March 2012, and has served as a member of the board of Coherus Biosciences, Inc., a public biotechnology company (Coherus), since October 2014. He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and he acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. Dr. Lawlis holds board positions at three private companies: AbSci, LLC, Reform Biologics LLC and Sutro Biopharma, Inc. Since October 2015, Dr. Lawlis has served as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.
理查德A. Meier于2006年12月加入了我们的董事会。2013年3月至2015年7月，梅尔先生担任欧文斯＆次要，全球医疗保健服务公司的执行副总裁兼首席财务官，他担任总统 -欧文斯＆次要的国际和执行副总裁兼首席财务官于2015年7月至2018年7月。2010年1月至2012年3月，Meier先生是一名全球医疗的Teleflex的执行副总裁兼首席财务官设备公司。从2007年11月到2009年5月，梅尔先生担任高级医疗光学总裁兼首席运营官，是由Abbott于2009年2月收购的全球眼科医疗器械公司。2002年4月至2007年11月期间，Meier先生不断担任Advanced Medical Optics’ Chief Financial Officer, while serving in a variety of additional senior operating roles. Prior to joining Advanced Medical Optics, Mr. Meier was the Executive Vice President and Chief Financial Officer of Valeant Pharmaceuticals, Inc. (formerly ICN Pharmaceuticals, Inc. (ICN)), from October 1999 to April 2002, and Senior Vice President & Treasurer from May 1998 to October 1999. Before joining ICN, Mr. Meier was an executive with the investment banking firm of Schroder & Co. Inc. in New York, from 1996. Prior to Mr. Meier’s experience at Schroder & Co., he held various financial and banking positions at Salomon Smith Barney, Manufacturers Hanover Corporation, Australian Capital Equity, and Greyhound Lines, Inc. Mr. Meier was a director of Staar Surgical Inc., an ophthalmic medical device company, from 2009 through June 2016. Mr. Meier holds a B.A. in economics from Princeton University.
David E.I. Pyott，医学博士(荣誉)，2016年1月加入BioMarin董事会。从1998年到2015年3月，他担任Allergan, Inc.(一家全球制药公司)的首席执行官。加入Allergan之前，Pyott博士曾担任Novartis营养部门的负责人，以及瑞士Novartis AG执行委员会的成员。他是Avery Dennison Corporation(一家公开的全球标签和包装材料公司)的首席董事和董事会成员，也是Alnylam Pharmaceuticals, Inc(一家公开的生物技术公司)的董事会成员;他还是荷兰皇家飞利浦(Royal Philips)的监事会成员，这是一家公共多元化医疗技术公司。他担任Bioniz Therapeutics, Inc.(一家私人生物技术公司)的董事长，以及Rani Therapeutics, LLC(一家私人生物技术公司)的董事会成员。他是伦敦商学院(London Business School)管理委员会副主席、国际眼科基金会理事会(International Council of Ophthalmology Foundation)主席、加州理工学院(California Institute of Technology)董事会成员和美国眼科学会基金会(Foundation of the American Academy of Ophthalmology)顾问委员会成员。从2000年到2014年，他担任Edwards Lifesciences Corp.(一家公共医疗设备公司)的董事会成员。他持有阿姆斯特丹大学欧罗巴研究所(Europa Institute at the University of Amsterdam)的国际和欧洲法律文凭，爱丁堡大学(University of Edinburgh)的医学荣誉学位和文学硕士学位，以及伦敦商学院(London Business School)的工商管理硕士学位。
Dennis J. Slamon，M.D.，Ph.D.加州大学洛杉矶分校医学系医学教授;加州大学洛杉矶分校Jonsson综合癌症中心临床/转化研究主任;露华浓/加州大学洛杉矶分校女性癌症研究项目主任^
Dennis J. Slamon，医学博士，2014年3月加入我们的董事会。他自1995年6月起担任加州大学洛杉矶分校Jonsson综合癌症中心的临床/转化研究主任，自1991年成立以来担任加州大学洛杉矶分校露华浓/加州大学洛杉矶分校女性癌症研究项目的负责人。1996年5月以来，他一直担任UCLA医学院的医学教授和血液/肿瘤学部主任，以及UCLA医学院的研究执行副主席。他还担任the National结直肠癌研究联盟(一个研究和筹款组织，促进结直肠癌的进展)的医疗顾问委员会的董事，他是肿瘤学转化研究(一个全球性的、非盈利的、学术的临床研究组织)的董事会成员。1970年，他获得华盛顿杰弗逊学院(Washington & Jefferson College)生物学荣誉学士学位，1975年毕业于芝加哥大学(University of Chicago)普利兹克医学院(Pritzker School of Medicine)，同年获得细胞生物学博士学位。他在芝加哥大学医院和诊所完成了实习和住院医师实习，于1978年成为总住院医师。一年后，他成为加州大学洛杉矶分校血液学/肿瘤科的研究员，目前他在医学院任职。